Overview

A Study of LY3502970 in Healthy Overweight and Obese Participants

Status:
Not yet recruiting
Trial end date:
2022-08-05
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company